SCHEMBL1590715

SCHEMBL1590715

CCOc1ncccc1C1(C(C(=O)O)C(=O)O)C(=O)Nc2ccc(Cl)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.41
NPC1 O15118 2/20 0.40
TSHR P16473 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
ADCY8 P40145 1/20 0.39
MAPK1 P28482 1/20 0.39
IP6K1 Q92551 1/20 0.38
CBX7 O95931 2/20 0.38
CDYL Q9Y232 2/20 0.38
CDYL2 Q8N8U2 1/20 0.38
CDY1; CDY1B Q9Y6F8 1/20 0.38
SNRNP200 O75643 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 1/20 0.38
SCN2A Q99250 1/20 0.35
SCN10A Q9Y5Y9 1/20 0.35
PGR P06401 1/20 0.34
ADAMTS5 Q9UNA0 1/20 0.34
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1590484 0.91 IDO1 (0.40) IDO1NPC1TSHRL3MBTL1ADCY8
SCHEMBL1590506 0.90 NPC1 (0.41) IDO1NPC1TSHRL3MBTL1ADCY8
SCHEMBL1588375 0.85 L3MBTL1 (0.39) NPC1TSHRL3MBTL1ADCY8MAPK1
SCHEMBL1480622 0.85 IP6K1 (0.39) L3MBTL1IP6K1PGR
SCHEMBL1590714 0.81 IDO1 (0.45) IDO1NPC1TSHRL3MBTL1ADCY8
SCHEMBL1590667 0.81 IDO1 (0.44) IDO1NPC1TSHRL3MBTL1ADCY8
SCHEMBL1589430 0.80 L3MBTL1 (0.40) NPC1TSHRL3MBTL1ADCY8MAPK1
SCHEMBL1590749 0.80 IDO1 (0.41) IDO1NPC1TSHRL3MBTL1ADCY8
SCHEMBL1590596 0.79 IDO1 (0.40) IDO1NPC1TSHRL3MBTL1ADCY8
SCHEMBL27821573 0.78 IDO1 (0.41) IDO1NPC1TSHRL3MBTL1ADCY8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150158845-A1 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES ABBVIE DEUTSCHLAND (DE) 2015-06-11 US disclosed
US-9023854-B2 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseases AbbVie Deutschland GmbH & Co. KG (DE) 2015-05-05 US disclosed
US-20110092516-A1 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES ABBOTT GMBH & CO. KG 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092516-A1 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES AVPR2, AVPR1B, AVPR1A IDO1 2206/4885NPC1 1989/4885TSHR 73/4885
US-20150158845-A1 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES AVPR2, AVPR1B, AVPR1A IDO1 2206/4885NPC1 1989/4885TSHR 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.